Organisation paid for research Program year 2025 Source: CMS Open Payments

Osman Dermatology

Neither a doctor nor a teaching hospital

Research payments

$579,489

29 payments

Through program year 2025, Osman Dermatology is reported as receiving $579,489 in research payments, across 29 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$225,991	7
2024	Research	$175,485	8
2023	Research	$108,060	5
2022	Research	$12,380	3
2021	Research	$26,208	1
2020	Research	$14,507	1
2019	Research	$16,857	4

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $579,489 29 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-To-Severe Atopic Dermatitis $148,761 4 payments
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-To-Severe Atopic Dermatitis $144,564 5 payments
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $92,352 3 payments
A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Assess the Efficacy Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-To-Severe Atopic Dermatitis $70,523 2 payments
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis $34,624 3 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3375880 in Adult Subjects With Moderate-To-Severe Atopic Dermatitis: the Admire Study $31,361 4 payments
A Phase 3 Multicenter Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-To-Severe Atopic Dermatitis $24,652 2 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $19,669 3 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $12,886 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata $99 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.